Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.38 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492974 | 0.76 | MAPK10 (0.46) | MAPK10NPC1RAB9APIK3C3MEN1 | |
| SCHEMBL3491112 | 0.72 | GSK3B (0.46) | MAPK10NPC1RAB9ATBK1LRRK2 | |
| SCHEMBL3493182 | 0.71 | KMT2A (0.52) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3491183 | 0.71 | GSK3B (0.52) | NPC1RAB9APIK3C3LCLAT1 | |
| SCHEMBL3493004 | 0.71 | THRB (0.53) | NPC1RAB9ALCLAT1NOTUM | |
| SCHEMBL3491649 | 0.70 | GSK3B (0.48) | MAPK10 | |
| SCHEMBL3491927 | 0.70 | MAPK10 (0.42) | MAPK10RAB9ATBK1LRRK2 | |
| SCHEMBL3490483 | 0.70 | SRC (0.45) | NPC1RAB9ALCLAT1NOTUM | |
| SCHEMBL3490446 | 0.70 | KDM4E (0.46) | NPC1RAB9ANOTUMMEN1KMT2A | |
| SCHEMBL26766195 | 0.69 | NOTUM (0.49) | NPC1RAB9ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | MAPK10 671/4885NPC1 1571/4885RAB9A 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.